Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm

Bibliography

• Klagsbrun M, Knighton D, Folkman J. Tumor angiogenesis activity in cells grown in tissue culture. Cancer Res 1976;36(1):110-4
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis. Adv Cancer Res 1974;19(0):331-58
   PubMedGoogle Scholar
• Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J Clin 1972;22(4):226-9
   PubMedGoogle Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
   PubMed Web of Science ®Google Scholar
• Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98(5):316-25
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-64
   PubMed Web of Science ®Google Scholar
• Kandel J, Bossy-Wetzel E, Radvanyi F, et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991;66(6):1095-104
   PubMed Web of Science ®Google Scholar
• Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991;22:339-47
   PubMedGoogle Scholar
• Fieth C, Kebig A, Mohr K. Angiogenesis inhibitors in cancer therapy. Bevacizumab against colon carcinoma. Pharm Unserer Zeit 2007;36(6):442-5
   PubMedGoogle Scholar
• Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007;67(12):1793-9
   PubMed Web of Science ®Google Scholar
• Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007;12(3):356-61
   PubMed Web of Science ®Google Scholar
• de Gramont A, Tournigand C, Andre T, et al. Targeted agents for adjuvant therapy of colon cancer. Semin Oncol 2006;33(6 Suppl 11):S42-5
   PubMed Web of Science ®Google Scholar
• Diaz-Rubio E. Vascular endothelial growth factor inhibitors in colon cancer. Adv Exp Med Biol 2006;587:251-75
   PubMedGoogle Scholar
• Lyseng-Williamson KA, Robinson DM. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs 2006;20(3):193-5
   PubMed Web of Science ®Google Scholar
• Cascone T, Troiani T, Morelli MP, et al. Antiangiogenic drugs in non-small cell lung cancer treatment. Curr Opin Oncol 2006;18(2):151-5
   PubMed Web of Science ®Google Scholar
• Kuczyk M, Kruck S, Merseburger AS. Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot. Urologe A 2007;46(5):504-8, 10
   PubMedGoogle Scholar
• Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-96
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• McKeage K, Wagstaff AJ. Sorafenib: in advanced renal cancer. Drugs 2007;67(3):475-83; discussion 84-5
   PubMed Web of Science ®Google Scholar
• Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005;41(12):773-84
   PubMed Web of Science ®Google Scholar
• Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008;134(2):379
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Merajver SD. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper–a review. Integr Cancer Ther 2002;1(4):327-37
   PubMedGoogle Scholar
• Miller RF, Engel RW. Interrelations of copper, molybdenum and sulfate sulfur in nutrition. Fed Proc 1960;19:666-71
   PubMedGoogle Scholar
• CF MI, El-Gallad TT, Bremner I, Weham G. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 1981;14(2):163-75
   PubMed Web of Science ®Google Scholar
• Clarke NJ, Laurie SH. The copper-molybdenum antagonism in ruminants. I. The formation of thiomolybdates in animal rumen. J Inorg Biochem 1980;12(1):37-43
   PubMed Web of Science ®Google Scholar
• Weber KM, Leaver DD, Wedd AG. The behaviour of thiomolybdates in in vitro systems. Br J Nutr 1979;41(2):403-5
   PubMed Web of Science ®Google Scholar
• Marcilese NA, Ammerman CB, Valsecchi RM, et al. Effect of dietary molybdenum and sulfate upon copper metabolism in sheep. J Nutr 1969;99(2):177-83
   PubMed Web of Science ®Google Scholar
• Mills CF, Monty KJ, Ichihara A, Pearson PB. Metabolic effects of molybdenum toxicity in the rat. J Nutr 1958;65(1):129-42
   PubMed Web of Science ®Google Scholar
• Joyce DA, Wade DN, Swanson BR. The pharmacokinetics of albumin conjugates of D-penicillamine in rats. Drug Metab Dispos 1989;17(2):208-11
   PubMed Web of Science ®Google Scholar
• Joyce DA. D-penicillamine pharmacokinetics and pharmacodynamics in man. Pharmacol Ther 1989;42(3):405-27
   PubMed Web of Science ®Google Scholar
• Brewer GJ. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med 2003;7(1):11-20
   PubMed Web of Science ®Google Scholar
• Vine AK, Brewer GJ. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Trans Am Ophthalmol Soc 2002;100:73-6; discussion 6-7
   PubMedGoogle Scholar
• Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, et al. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 1991;48(1):42-7
   PubMed Web of Science ®Google Scholar
• Lee VE, Schulman JM, Stiefel EI, et al. Reversible precipitation of bovine serum albumin by metal ions and synthesis, structure and reactivity of new tetrathiometallate chelating agents. J Inorg Biochem 2007;101(11):1707-18
   PubMed Web of Science ®Google Scholar
• Song M, Song Z, Barve S, et al. Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 2008;325(2):409-16
   PubMed Web of Science ®Google Scholar
• Zhou H, Fischer HP. Hereditary hemochromatosis, alpha-1-antitrypsin deficiency and Wilson's disease : pathogenesis, clinical findings and pathways to diagnosis. Pathologe 2008;29(1):73-83
   PubMed Web of Science ®Google Scholar
• Machado AA, Deguti MM, Genschel J, et al. Neurological manifestations and ATP7B mutations in Wilson's disease. Parkinsonism Relat Disord 2008;14(3):246-9
   PubMed Web of Science ®Google Scholar
• Sinha S, Taly AB. Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap. J Neurol Sci 2008;264(1-2):129-32
   PubMed Web of Science ®Google Scholar
• Brewer GJ. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood) 2001;226(7):665-73
   PubMed Web of Science ®Google Scholar
• Karunajeewa H, Wall A, Metz J, Grigg A. Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease. Aust N Z J Med 1998;28(2):215-6
   PubMedGoogle Scholar
• Brewer GJ. Interactions of zinc and molybdenum with copper in therapy of Wilson's disease. Nutrition 1995;11(1 Suppl):114-6
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994;51(6):545-54
   PubMed Web of Science ®Google Scholar
• Walshe JM. Thiomolybdates in the treatment of Wilson's disease. Arch Neurol 1992;49(2):132-3
   PubMedGoogle Scholar
• Ziche M, Gullino PM. Angiogenesis and neoplastic progression in vitro. J Natl Cancer Inst 1982;69(2):483-7
   PubMed Web of Science ®Google Scholar
• Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 1982;69(2):475-82
   PubMed Web of Science ®Google Scholar
• Khan GN, Merajver SD. Modulation of angiogenesis for cancer prevention: strategies based on antioxidants and copper deficiency. Curr Pharm Des 2007;13(35):3584-90
   PubMed Web of Science ®Google Scholar
• Hassouneh B, Islam M, Nagel T, et al. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther 2007;6(3):1039-45
   PubMed Web of Science ®Google Scholar
• Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62(17):4854-9
   PubMed Web of Science ®Google Scholar
• Pan Q, Bao LW, Kleer CG, et al. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther 2003;2(7):617-22
   PubMed Web of Science ®Google Scholar
• Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res 2003;1(10):701-6
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Johnson V, Dick RD, Kluin KJ, et al. treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 1996;53:1017-25
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Ullenbruch MR, Dick R, et al. Tetrathiomolybdate therapy protects against bleomycin-indcued pulmonary fibrosis in mice. J Lab Clin Med 2003;141:210-16
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000;6(1):1-10
   PubMed Web of Science ®Google Scholar
• Henry NL, Dunn R, Merjaver S, et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 2006;71(3-4):168-75
   PubMed Web of Science ®Google Scholar
• Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;9(5):1666-72
   PubMed Web of Science ®Google Scholar
• Gartner EM, Griffith KA, Pan Q, et al. A pilot trial of the anti-angio`genic copper lowering agent tettrathiomolybdate in combination with irnotecan, 5-fluorouracil and leucovorin for metastatic colonc acner. Invest New Drugs 2009;27:159-65
   PubMed Web of Science ®Google Scholar
• Juarez JC, Manuia M, Burnett ME, et al. Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci USA 2008;105(20):7147-52
   PubMed Web of Science ®Google Scholar
• Donate F, Juarez JC, Burnett ME, et al. Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br J Cancer 2008;98(4):776-83
   PubMed Web of Science ®Google Scholar